Editas Medicine (LTS:0IFK) Additional Paid-In Capital : $1,606.86 Mil(As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Editas Medicine Additional Paid-In Capital?

Editas Medicine's quarterly additional paid-in capital increased from Sep. 2024 ($1,598.15 Mil) to Dec. 2024 ($1,602.44 Mil) and increased from Dec. 2024 ($1,602.44 Mil) to Mar. 2025 ($1,606.86 Mil).

Editas Medicine's annual additional paid-in capital increased from Dec. 2022 ($1,442.41 Mil) to Dec. 2023 ($1,580.24 Mil) and increased from Dec. 2023 ($1,580.24 Mil) to Dec. 2024 ($1,602.44 Mil).

Editas Medicine Additional Paid-In Capital Historical Data

The historical data trend for Editas Medicine's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Editas Medicine Additional Paid-In Capital Chart

Editas Medicine Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

1,058.82

1,411.83

1,442.41

1,580.24

1,602.44

Editas Medicine Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															1,588.02	1,593.35	1,598.15	1,602.44	1,606.86

Editas Medicine Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Editas Medicine Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Editas Medicine's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Editas Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (LTS:0IFK) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

EDIT:USA 8EM:Germany 8EM:Germany

Address

11 Hurley Street, Cambridge, MA, USA, 02141

Website

https://www.editasmedicine.com

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Editas Medicine Headlines

No Headlines